Latest News

Amylin Pharmaceuticals and Takeda Enter into Worldwide Agreement to Co-Develop and Commercialize Compounds for Obesity

Echo Therapeutics Announces Significant Advance in Development of its One-Piece, Needle Free Symphony tCGM Biosensor

Norgine acquires cetilistat

Sanofi-aventis and Wellstat Therapeutics enter into an Exclusive Worldwide Licensing Agreement for novel oral agent to treat Type II Diabetes

Tolerx Presents Otelixizumab Phase 2 Dose Optimization Data at the IDF's 20TH World Diabetes Congress

Shire Targets Fourth Quarter Filing of BLA for REPLAGAL

Galapagos expands strategic alliance in metabolic disease with Merck & Co., Inc

Data on VIVUS' Qnexa To Be Featured at The Obesity Society Annual Meeting

Boehringer Ingelheim`s diabetes pipeline continues to advance as the Company announces conclusion of robust Phase III pivotal trials programme for linagliptin

Arena Pharmaceuticals Reports Positive, Highly Significant BLOSSOM Trial Results for Weight Management; NDA Submission on Track for December

More news... | RSS Feed...

Most Viewed

Galapagos expands strategic alliance in metabolic disease with Merck & Co., Inc

Sanofi-aventis and Wellstat Therapeutics enter into an Exclusive Worldwide Licensing Agreement for novel oral agent to treat Type II Diabetes

Data on VIVUS' Qnexa To Be Featured at The Obesity Society Annual Meeting

Tolerx Presents Otelixizumab Phase 2 Dose Optimization Data at the IDF's 20TH World Diabetes Congress

Shire Targets Fourth Quarter Filing of BLA for REPLAGAL

Aegis Therapeutics and Albany Medical College Expand Collaboration for Novel Oral Anti-Obesity Drug

Arena Pharmaceuticals Reports Positive, Highly Significant BLOSSOM Trial Results for Weight Management; NDA Submission on Track for December

Boehringer Ingelheim`s diabetes pipeline continues to advance as the Company announces conclusion of robust Phase III pivotal trials programme for linagliptin

ConjuChem Announces Fiscal 2009 Third Quarter Financial Results

Amylin Pharmaceuticals and Takeda Enter into Worldwide Agreement to Co-Develop and Commercialize Compounds for Obesity

Therapeutic Target

Cardiovascular

Dermatology

Endocrine and Metabolic

Gastroenterology

Genitourinary

Hematology

Immunology and Allergy

Infection

Musculoskeletal

Neurology

Obstetrics and Gynecology

Oncology

Ophthalmology

Psychiatry

Pulmonary

Categories

Deals and Alliances

Development

Financial Results

Financings

Intellectual Property

Regulatory

Press releases

Deals review

Headlines

PR Newswire